信号传导和转录激活因子3与肿瘤治疗抵抗  

Signal transducers and activators of transcription3 andtumor therapeutic resistance

作　　者：贾立峰[1] 李晓明[1] 

机构地区：[1]白求恩国际和平医院耳鼻咽喉头颈外科,石家庄050082

出　　处：《国际耳鼻咽喉头颈外科杂志》2017年第1期23-26,共4页International Journal of Otolaryngology-Head and Neck Surgery

基　　金：河北省应用基础研究计划重点基础研究项目（14967721D）,河北省自然科学基金面上项目（H2012505005）联合资助

摘　　要：治疗抵抗是造成恶性肿瘤复发、远处转移并最终导致患者死亡的最直接原因。当前，亟需新的药物和方法来消除和抑制治疗抵抗的发生，以提高肿瘤患者预后。研究显示，信号传导和转录激活因子3（signal transducers and activators of transcription3，STAT3）的激活与许多肿瘤细胞的治疗抵抗密切相关，抑制STAT3激活可逆转肿瘤细胞对放化疗的抵抗，因此STAT3极有可能成为攻克恶性肿瘤的关键靶点。Therapeutic resistance, the most important tumor igenic factor responsible for the cancer patients death, is the major cause leading to tumor relapse and metastasis, which poses a great difficulty in choosing therapeutic methods. Therefore, new treatment drugs/modalities are required tode feat treatment-resistant and improve the survival/outcome of tumor patients. Activation of signal transducers and activators of transcription3 （STAT3） has been found associated with initiation of therapeutic resistance and blockage of the activation can avoid the tumor therapeutic resistance. As a result, STAT3 protein has been considered as an ideal therapeutic target forover coming the resistance to cure cancer patients.

关 键 词：肿瘤 STAT3转录因子 治疗抵抗 

分 类 号：R73-3[医药卫生—肿瘤]